| Literature DB >> 31199503 |
Laura Costas1, Jon Frias-Gomez1, Magdalena Guardiola1, Yolanda Benavente1,2, Marta Pineda3, Miquel Á Pavón1,4, José M Martínez5, Maite Climent5, Marc Barahona5, Júlia Canet3, Sonia Paytubi1, Mónica Salinas3, Luis Palomero6, Ilaria Bianchi7, Jaume Reventós8, Gabriel Capellà3,4, Mireia Diaz1,4, August Vidal4,9, Josep M Piulats4,10, Álvaro Aytés6, Jordi Ponce5, Joan Brunet3,4,11, Francesc X Bosch1,4, Xavier Matias-Guiu4,9, Laia Alemany1,2, Silvia de Sanjosé2,12.
Abstract
Due to the anatomical continuity of the uterine cavity with the cervix, genomic exploitation of material from routine Pap smears and other noninvasive sampling methods represent a unique opportunity to detect signs of disease using biological material shed from the upper genital tract. Recent research findings offer a promising perspective in the detection of endometrial cancer, but certain questions need to be addressed in order to accelerate the implementation of novel technologies in a routine screening or clinical setting. We discuss here new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods with a special focus on public health classic screening criteria, highlighting current gaps in knowledge.Entities:
Keywords: biomarkers; early detection; endometrial cancer; genomics; pap smears; screening
Mesh:
Substances:
Year: 2019 PMID: 31199503 DOI: 10.1002/ijc.32514
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396